The use of interconnected β-tricalcium phosphate as bone substitute after curettage of benign bone tumours

2010 ◽  
Vol 21 (4) ◽  
pp. 235-241 ◽  
Author(s):  
Pavel Šponer ◽  
Karel Urban ◽  
Tomáš Kučera ◽  
Aleš Kohout ◽  
Jindra Brtková ◽  
...  
Keyword(s):  
Tricalcium Phosphate ◽  
Bone Substitute ◽  
Bone Tumours ◽  
Benign Bone Tumours

scholarly journals Biphasic bone substitute and fibrin sealant for treatment of benign bone tumours and tumour-like lesions

2011 ◽  
Vol 36 (1) ◽  
pp. 139-148 ◽  
Author(s):  
Stephan Reppenhagen ◽  
Johannes C. Reichert ◽  
Lars Rackwitz ◽  
Maximilian Rudert ◽  
Peter Raab ◽  
...  
Keyword(s):  
Fibrin Sealant ◽  
Bone Substitute ◽  
Bone Tumours ◽  
Benign Bone Tumours

scholarly journals Use of purified beta-tricalcium phosphate for filling defects after curettage of benign bone tumours

2006 ◽  
Vol 30 (6) ◽  
pp. 510-513 ◽  
Author(s):  
M. Hirata ◽  
H. Murata ◽  
H. Takeshita ◽  
T. Sakabe ◽  
Y. Tsuji ◽  
...  
Keyword(s):  
Tricalcium Phosphate ◽  
Bone Tumours ◽  
Beta Tricalcium Phosphate ◽  
Benign Bone Tumours

Outcomes of Surgery for Enchondromas within the Hand

2021 ◽  
Vol 23 (5) ◽  
pp. 325-334
Author(s):  
Andrzej Żyluk
Keyword(s):  
Bone Graft ◽  
Bone Defect ◽  
Bone Substitute ◽  
Pathological Fracture ◽  
Bone Tumours ◽  
Cold Sensitivity ◽  
First Line ◽  
Hand Phalanges ◽  
Benign Bone Tumours

Background. Enchondromas are the most common benign bone tumours found in the hand. They are usually accidentally diagnosed on an X-ray, because they grow asymptomatically. In some cases, a pathological fracture of the involved phalanx may be the first sign. The objective of this study was to assess the results of operative treatment of enchondromas involving hand phalanges and metacarpals. Material and methods. The study group consisted of 24 patients, 16 women (67%) and 8 men, (33%), aged a mean of 31 years, who were operated on at our centre. The surgery consisted in curettage, and - in most cases - filling the bone defect with either a bone graft or a bone substitute. Follow-up assessment was performed over the telephone in 17 patients (79% of the group) at a mean of 2 years after surgery. Results. Half of the patients were asymptomatic and fully recovered functionally, whereas the other half complained of some not troublesome symptoms such as scar discomfort, limitation of finger movement or cold sensitivity. No differences were observed with regard to the material used for filling of the bone defect following curettage. Two cases of recurrence were noted after surgery: one in the bone substitute group and one in the bone graft group. Conclusions. 1. Enchondromas are the most common benign bone tumours encountered in bones of the hand. 2. The first line treatment in these lesions is curettage and filling of the bone defect with a bone sub­stitute or cancellous bone graft. 3. Both the results of the present study and literature data show that the approach to managing the tu­mour cavity after curettage has no significant effect on outcomes, which are essentially satisfactory.

scholarly journals Pitfalls in the diagnosis of common benign bone tumours in children

2014 ◽  
Vol 5 (6) ◽  
pp. 645-655 ◽  
Author(s):  
Dana I. Dumitriu ◽  
Renaud Menten ◽  
Philippe Clapuyt
Keyword(s):  
Bone Tumours ◽  
Benign Bone Tumours

Tumours

2021 ◽  
pp. 213-218
Keyword(s):  
Bone Tumours ◽  
Practice Questions ◽  
Benign Bone Tumours

This chapter contains practice questions based on a broad range of orthopaedic topics that may be encountered within the ‘Adult Pathology’ station of the FRCS (Trauma and Orthopaedics) viva examination. The topics covered malignant and benign bone tumours including osteosarcoma and osteochondroma among other conditions.

scholarly journals Supplementation with 45S5 Bioactive Glass Reduces In Vivo Resorption of the β-Tricalcium-Phosphate-Based Bone Substitute Material Vitoss

2019 ◽  
Vol 20 (17) ◽  
pp. 4253 ◽  
Author(s):  
Fabian Westhauser ◽  
Christopher Essers ◽  
Maria Karadjian ◽  
Bruno Reible ◽  
Gerhard Schmidmaier ◽  
...  
Keyword(s):  
Bioactive Glass ◽  
Tricalcium Phosphate ◽  
Bone Substitute ◽  
Degradation Kinetics ◽  
Bone Substitutes ◽  
Micro Computed Tomography ◽  
Immunodeficient Mice ◽  
Bone Substitute Materials ◽  
Osseous Regeneration

Compared to other materials such as 45S5 bioactive glass (BG), β-tricalcium phosphate (β-TCP)-based bone substitutes such as Vitoss show limited material-driven stimulation of osteogenesis and/or angiogenesis. The unfavorable degradation kinetics of β-TCP-based bone substitutes may result in an imbalance between resorption and osseous regeneration. Composite materials like Vitoss BA (Vitoss supplemented with 20 wt % 45S5-BG particles) might help to overcome these limitations. However, the influence of BG particles in Vitoss BA compared to unsupplemented Vitoss on osteogenesis, resorption behavior, and angiogenesis is not yet described. In this study, Vitoss and Vitoss BA scaffolds were seeded with human mesenchymal stromal cells before subcutaneous implantation in immunodeficient mice for 10 weeks. Scaffold resorption was monitored by micro-computed tomography, while osteoid formation and vascularization were assessed by histomorphometry and gene expression analysis. Whilst slightly more osteoid and improved angiogenesis were found in Vitoss BA, maturation of the osteoid was more advanced in Vitoss scaffolds. The volume of Vitoss implants decreased significantly, combined with a significantly increased presence of resorbing cells, whilst the volume remained stable in Vitoss BA scaffolds. Future studies should evaluate the interaction of 45S5-BG with resorbing cells and bone precursor cells in greater detail to improve the understanding and application of β-TCP/45S5-BG composite bone substitute materials.

Treatment of benign bone tumours using external fixation

2007 ◽  
Vol 89-B (8) ◽  
pp. 1077-1083 ◽  
Author(s):  
H. Tsuchiya ◽  
A. F. Morsy ◽  
H. Matsubara ◽  
K. Watanabe ◽  
M. E. Abdel-Wanis ◽  
...  
Keyword(s):  
External Fixation ◽  
Bone Tumours ◽  
Benign Bone Tumours

Novel Unidirectional Porous β-Tricalcium Phosphate Used as a Bone Substitute after Excision of Benign Bone Tumors of the Hand: A Case Series

2018 ◽  
Vol 23 (03) ◽  
pp. 424-429 ◽  
Author(s):  
Akira Ikumi ◽  
Toru Funayama ◽  
Toshinori Tsukanishi ◽  
Hiroshi Noguchi ◽  
Masashi Yamazaki
Keyword(s):  
Bone Formation ◽  
Tricalcium Phosphate ◽  
Bone Substitute ◽  
Bone Tumors ◽  
Animal Studies ◽  
Case Series ◽  
Clinical Results ◽  
Benign Bone Tumors ◽  
Tumors Of The Hand ◽  
Satisfactory Clinical Result

Unidirectional porous β-tricalcium phosphate (UDPTCP; Affinos®, Kuraray, Tokyo, Japan) has been in clinical use since 2015. Animal studies have confirmed the excellent potential of UDPTCP with regard to bone formation and material absorption. We present the first three clinical cases using UDPTCP as a bone substitute after curettage of benign bone tumors of the hand. All three patients were males, 29-, 30- and 81-years-old, two having a diagnosis of enchondroma and the other, a bone ganglion, with a pathological fracture identified in one case. Over a mean follow-up of 10 months, all patients achieved satisfactory clinical result, with no adverse events of UDPTCP noted. Radiographic evidence of good bone formation and material absorption was observable over the postoperative course. UDPTCP provided satisfactory clinical results, with good biocompatibility and fast resorption characteristics. Therefore, UDPTCP could provide a safe and reliable filling substitute for bone defects following curettage of small bone tumors.

Sign in / Sign up

Export Citation Format

Share Document